Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Dyne Bio Inc. is a South Korean biotechnology company founded in 1999 that specializes in life science research reagents, functional biomaterials, and organ-on-a-chip technology. The company provides a comprehensive portfolio of products including PCR enzymes, nucleic acid staining solutions such as LoadingSTAR, and DNA/RNA purification kits. Dyne Bio is a pioneer in developing bioactive compounds from marine sources, notably neoagarooligosaccharides (Dyne-NAO) derived from red algae, which are targeted at improving metabolic health and immune homeostasis. Additionally, the company has developed the 3-D HuChip platform, an advanced organ-on-a-chip system designed to replicate human organ functions for pharmacokinetics and pharmacodynamics research. Dyne Bio operates globally, with its functional materials receiving regulatory recognitions such as US FDA GRAS and NDI status.
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on Dynebio.